HomeAI · summaries
Storia in 2 fonti
Sanofi’s Pompe disease treatment successor passes Phase 3 test in babies
Sanofi said its enzyme replacement therapy succeeded in a registrational trial in a severe form of Pompe disease, paving the way for a key label expansion in the US.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Sanofi’s Pompe disease treatment successor passes Phase 3 test in babies
Sanofi said its enzyme replacement therapy succeeded in a registrational trial in a severe form of Pompe disease, paving the way for a key label expansion in the US.
- ·
benzinga.com
Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints - Sanofi (NASDAQ:SNY)
Sanofi says Nexviazyme met all Phase 3 trial endpoints in infantile Pompe disease, supporting a planned US label expansion filing in 2026.